Wall Street Sees Woodcock Commissionership As Positive for Aducanumab, But Eyes Should Be On Cavazzoni

 
• By Sarah Karlin-Smith
  
Acting CDER Director Patrizia Cavazzoni may have to think more about aducanumab, but Acting US FDA Commissioner Janet Woodcock is front of mind for Wall Street analysts. • Source: photo illustration

More from Agency Leadership

More from Pink Sheet